Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Investor Day (October 2007)
11 slides from Teva Pharmaceutical Industries's investor day presentation, Oct 15, 2007
Slide 1: Teva Innovative Ventures
Aharon Schwartz, Ph.D. Vice President, Teva Innovative Ventures October 15, 2007 Forward-Looking Statements TODAY’S PRESENTATION CONTAINS FORWARD LOOKING STATEMENTS WHICH EXPRESS THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT. SUCH STATEMENTS ARE BASED ON CURRENT EXPECTATIONS AND INVOLVE A NUMBE
Slide 2: TIV Investments: Additional Avenue to Expand Teva's Pipeline
TIV Investments: Additional Avenue to Expand Teva’s Pipeline Direct Inv. GO/ Promising NO-GO R&D Project/Technology Exercise Indirect Inv. Option • Teva provides much needed resources to the portfolio companies through Teva’s IR&D: – Chemical synthesis – Analytical & preclinical expertise Add to Tev
Slide 3: Teva Acquired Strategic Rights in BMI Companies; CBI Indirect Investment
Teva Acquired Strategic Rights in 2 BMI Companies Bio Medical Investments Biocontrol Implantable Nerve Simulation Direct Transpharma investment TSD Delivery + License Gamida Cell Direct investment Cell Therapy + Joint Venture Remon XTL Mini Implants MABs Hep B,C CBI: Teva’s More Recent Indirect Inve
Slide 4: Teva Acquired Strategic Rights in CBI Companies
Teva Acquired Strategic Rights in 4 CBI Companies Clal Biotech – Main Cos. I.D.M. Compugen (IDMI) (CGEN) Andromeda Buyout Option PIII Diabetes MediWound Direct investment PIII Burn Debridement + License CureTech Direct investment + PII MABs for Cancer Buy-out Option N.S.T. Direct investment Targetin
Slide 5: Examples of Later Stage Opportunities
Teva Has Equity in > 15 Start-up Companies Teva has strategic rights in many of the investments Equity in companies Strategic Rights D-Pharm Cellcure TransPharma Gamida-Cell Biocontrol IDM Proteologics Curetech Remon Compugen Andromeda NST XTL VBL MediWound Vaccinex Rosetta TIV Investments Examples
Slide 6: Gamida-Cell JV/StemEx
Gamida-Cell JV/StemExTM TIV/Investments - Gamida Cell JV 2003 Direct Inv. Gamida-Cell Exercise Phase I/II (StemExTM) JV Option Indirect Inv. (BMI) (2006) • In 2003, Teva invested in Gamida and obtained an option to enter into a JV upon pre-agreed terms • In 2006, Teva exercised the JV option to comm
Slide 7: StemEx Should Reach Market in 2010
StemExTM Should Reach Market in 2010 2007 2008 2009 2010 Phase III Study Submission FPI Pivotal Study (~100 patients) Curetech/CT-011 7
Slide 8: Curetech CT-011 Should Reach the Market by 2012
TIV/Investments - Curetech 2006 Direct Inv. Curetech Inv. Buyout (CT-011) Phase II Option Phase III Indirect Inv. Option (CBI) • In 2006, Teva invested in Curetech (to fund CT-011 Phase II trial) and obtained two options – Option for follow-on investment (to fund Phase III trial) Add to – Option to
Slide 9: MediWound/Debrase
MediWound/DebraseTM TIV/Investments - MediWound 2007 Direct Inv. EU/US MediWound (DebraseTM) Phase III Marketing Indirect Inv. Options (CBI) • In 2007, Teva invested in MediWound and obtained marketing rights to DebraseTM in ROW and options to extend such rights to EU and US upon additional Add to i
Slide 10: Debridement: current standard of care; Treatment with Debrase
Debridement: current standard of care • Surgical (mandatory in full thickness wounds) 6% – Trauma 22% – Loss of healthy tissues • 72% excessive excision – Blood loss • 22% Insufficient excision Complex anesthesia • 6% got it right – 72% – Surgeons & skills – Facilities – Cost • Conservative (non-sur
Slide 11: Debrase Should Reach the EU Market by 2010; US 2011
DebraseTM Should Reach the EU Market by 2010; US 2011 2007 2008 2009 2010 2011 Phase III EU Study EU Submission Phase III US Study US Submission 11
Teva Pharmaceutical Industries — Investor Day (October 2007) on 6ix